EPAS1 and nonpapillary renal cell carcinoma: ARC-20A (NCT05536141), Phase 1 dose-escalation and dose-expansion study, is to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with ccRCC and other solid tumors.